Dupilumab Hits Asthma Harder Than It Does Eczema
When a drug that was originally put together to help eczema sufferers is now slashing severe asthma attacks in half, you know you’ve stumbled on something big. That’s the gist of the new study published this week that could open up a whole new world of treatments for wheezy all‑stars.
From Chapped Skin to Chic Operas in the Lungs
- What’s the drug? Dupilumab, better known by its brand name Dupixent, was cleared by the FDA last year for treating eczema. The company behind it, Regeneron Pharmaceuticals, set a hefty price tag of $37,000 a year.
- The study examined over 2,000 patients with moderate to severe asthma. They were given 200‑300 mg injections every two weeks for a full year.
- Results? Asthma attacks that could be deadly dropped by almost 50%, and lung function actually improved. For patients with high eosinophil counts, the drop was a jaw‑dropping two‑thirds.
- Side effects were pretty mild – just some pain and swelling at the injection site.
- Deaths? In the trial, five on dupilumab and three on placebo died, but all had multiple serious conditions, so the drug wasn’t blamed.
Why It Matters
The study makes a solid case for dupilumab getting a green light for severe asthma. If that happens, three other biologics – mepolizumab, reslizumab, and benralizumab – could join the party too.
The editorial in the New England Journal of Medicine calls it a clear advancement in asthma care, but also warns that none of these are miracle cures – they just cut the symptoms. The real puzzle is figuring out which one is best for you, and the editors suggest straight‑ahead, head‑to‑head trials to answer that.
Unpacking the Future of Asthma Treatment
We’re in a time when biotech can produce drugs that mimic natural biology (think human cells, animal extracts, or microbial proteins). That’s why the “biologics” buzz is louder than ever. Yet, choosing the right drug can get tricked by marketing muscle.
“Without more data, we’ll end up picking the manufacturer with the loudest megaphone,” the editors warned. “Our patients deserve smarter choices.”
Bottom line: a drug that helped soothe itchy skin now helps breathe easier for thousands, and that’s a win for everyone on the asthma frontline.
